Onkologie. 2012:6(2):68-70

Antiangiogenic therapy for ovarian cancer

František Nový
Roche, s. r. o.

At the end of last year, the options of treatment for ovarian cancer expanded to include antiangiogenic therapy. The European Commission

approved the use of bevacizumab (Avastin®) for a new indication: “Avastin in combination with carboplatin and paclitaxel is indicated for

the front-line treatment of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.” Since

2005, bevacizumab has been indicated for the treatment of metastatic colorectal cancer and, since 2007, for the treatment of metastatic

breast and kidney cancers and recurrent or metastatic non-small-cell lung cancer.

Keywords: angiogenesis, antiangiogenic therapy, targeted therapy, ovarian cancer

Published: April 23, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nový F. Antiangiogenic therapy for ovarian cancer. Onkologie. 2012;6(2):68-70.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803. Go to original source... Go to PubMed...
    2. Ferrara N, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004; 3: 391-400. Go to original source... Go to PubMed...
    3. Burger RA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473-2483. Go to original source... Go to PubMed...
    4. Burger RA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 2012; 28 (Suppl; abstr LBA1): 18s. Go to original source...
    5. Perren TJ, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26): 2484-2496. Go to original source... Go to PubMed...
    6. Perren TJ, et al. ICON7: A phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Annals of Oncology 2010; 21(Suppl 8: Abstract Book of the 35th ESMO Congress, abstract LBA4).
    7. Kristensen G, et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 2011; 29(Suppl; abstr LBA5006). Go to original source...
    8. Aghajanian C, et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinumsensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29(Suppl; abstr LBA5007). Go to original source...
    9. Souhrn informaci o produktu Avastin, www.sukl.cz.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.